Skip to main content
 

AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib

AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib

It is estimated that more than 5 million people in the United State are diagnosed with NVAF and an additional 3 million have AFib and don’t know it (Colilla S et al. Am J Cardiol.2014;pii: S0002-9149(13)-1288). The BMS/Pfizer Alliance and AHA are working together to identify undiagnosed patients and provide digital tools to manage the condition. The first phase of this study involves the development of a screening tool using a combination of pharmacy, hospital, claims and EHR data in order to identify patients at high risk for having or developing AFib. AHA and its team of expert advisors are designing the tool with the intent of practical clinical implementation and scalability. Success of this tool has the potential to save millions of lives by reducing the risk of stroke in AFib patients who don’t even know they have AFib.

More News

  • Highlights from the Health Innovation Pavilion at AHA22

  • Health Tech + Health Equity: tackling complex health disparities with scalable solutions, ensuring equitable health for all.

  • AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib